|
Aug 8
|
Vaxart CEO Issues Letter to Stockholders
|
|
Aug 7
|
The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates
|
|
Aug 6
|
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
|
|
Jul 24
|
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
|
|
Apr 16
|
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23
|
|
Mar 27
|
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 22
|
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 21
|
Q4 2024 Vaxart Inc Earnings Call
|
|
Mar 21
|
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...
|
|
Mar 20
|
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 20
|
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
|
|
Mar 13
|
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
|
|
Mar 11
|
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
|